



Daily Marijuana Use Predicts HIV Seroconversion Among Black Men Who Have Sex with Men and Transgender Women in Atlanta, GA

Justin Knox^{1,2} · Grace Hwang³ · Adam W. Carrico⁴ · Dustin T. Duncan⁵ · Ryan J. Watson⁶ · Lisa A. Eaton⁶

Accepted: 20 January 2022 / Published online: 30 January 2022

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

We evaluated whether different types of substance use predicted HIV seroconversion among a cohort of 449 Black men who have sex with men (MSM) and transgender women (TGW). A community-based sample was recruited in Atlanta, GA between December 2012 and November 2014. Participants completed a survey and were tested for STIs (Chlamydia and gonorrhoeae using urine samples and rectal swabs) at baseline. HIV testing was conducted at 12-months post enrollment. Multivariable binary logistic regression was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CI) for associations between substance use and HIV seroconversion. By 12-month follow-up, 5.3% ($n=24$) of participants seroconverted. In multivariable analyses, daily marijuana use was positively associated with HIV seroconversion (aOR 3.07, 95% CI 1.11–8.48, $P=0.030$). HIV incidence was high and daily marijuana use was associated with a more than threefold increased odds of HIV seroconversion among a community-based cohort of Black MSM and TGW.

Keywords HIV incidence · Marijuana · Substance use · Men who have sex with men (MSM) · Transgender women (TGW)

Resumen

Evaluamos si diferentes tipos de uso de sustancias predijeron la seroconversión del VIH entre una cohorte de 449 hombres que tienen sexo con hombres (HSH) y mujeres transgénero (TGW) de raza negra. Se reclutó una cohorte en la comunidad en Atlanta, GA, entre diciembre de 2012 y noviembre de 2014. Los participantes completaron una encuesta y se les hizo una prueba de infecciones de transmisión sexual (clamidia y gonorrea usando muestras de orina e hisopos rectales) al inicio del estudio. Los participantes completaron una prueba del VIH al final del estudio. Se utilizó la regresión logística binaria multivariable para estimar proporciones de probabilidades ajustadas (aOR) y los intervalos de confianza (CI) del 95% para las asociaciones entre el uso de sustancias y la seroconversión del VIH. A los 12 meses de seguimiento, 5,3% ($n=24$) de los participantes se seroconvirtieron. En análisis multivariable, el consumo diario de marihuana se asoció positivamente con la seroconversión del VIH (aOR 3.07, 95% CI 1.11–8.48, $P=0.030$). La incidencia del VIH fue elevada y el uso diario de marihuana se asoció con un aumento de más de 3 veces en las probabilidades de seroconversión del VIH entre una cohorte de HSH y TGW de raza negra reclutado por la comunidad.

✉ Justin Knox
justinryanknox@gmail.com

Grace Hwang
graceweihwang@gmail.com

Adam W. Carrico
a.carrico@miami.edu

Dustin T. Duncan
dd3018@cumc.columbia.edu

Ryan J. Watson
ryan.j.watson@uconn.edu

Lisa A. Eaton
lisa.eaton@uconn.edu

¹ Department of Psychiatry, Columbia University, 722 West 168th street, New York 10032, USA

² HIV Center for Behavioral Studies, New York State Psychiatric Institute, New York, USA

³ Department of Sociomedical Sciences, Columbia University, New York, USA

⁴ Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, USA

⁵ Department of Epidemiology, Columbia University, New York, USA

⁶ Department of Human Development and Family Sciences, University of Connecticut, Storrs, USA

Introduction

In 2019, the United States (US) Department of Health and Human Services launched the Ending the HIV Epidemic initiative (EHE), the aims of which are to reduce new HIV infections in the US by 90% by 2030 by scaling up key HIV prevention and treatment strategies [1]. Under EHE, prioritization is given to 50 local areas that account for more than half of new HIV diagnoses, which includes Atlanta, GA, the site of the current study, as well as populations most heavily impacted by HIV, such as gay, bisexual and other cisgender men who have sex with men (MSM) and transgender women who have sex with men (TGW) [1]. According to the most recent National HIV Surveillance System Report, new HIV infections in the US decreased by 8% from 2015 to 2019, and much of this was a result of larger declines among MSM, particularly younger (ages 13–24) MSM [2].

Nevertheless, MSM still comprise the largest group living with HIV in the US, accounting for 75% of all new infections annually [3–5]. Stark racial disparities in new HIV infections exist among MSM, especially among Black MSM [4–8]. Black MSM account for one out of every four new HIV diagnoses [9]. Rates of HIV diagnoses among Black MSM have also varied by age, with increases observed specifically among young Black MSM, in contrast to decreases among other at-risk sub-populations during the same time period [10, 11]. The CDC estimates that, based on current rates of HIV infection, one in two Black MSM will be infected with HIV during their lifetime [10].

TGW also remain a population heavily impacted by HIV [11–14]; with stark racial disparities characterizing the epidemic among TGW in the US [12, 15]. For example, in a seroprevalence study of TGW in 3 US cities, there were three-fold more undiagnosed HIV infections in TGW of color compared to White TGW [15].

This HIV crisis among Black MSM and TGW in the US is most pressing in the Southeastern US, which is home to 21 of the 25 metropolitan areas with the highest prevalence of HIV [16]. HIV infection is hyper-endemic (sustained at levels of 15% or higher) among Black MSM and TGW in these areas [16]. In Atlanta, Georgia, the estimated prevalence of HIV is 46% among Black MSM, which is more than three times higher than the HIV prevalence among white MSM (13%) [17]. HIV incidence was nearly three times higher among Black MSM compared to white MSM, and was the highest among young (18–24 years) Black MSM [18].

Despite this increased burden and risk of HIV infection among Black MSM and TGW, with a focus in the US Southeast, very little research, thus far, has studied predictors of HIV incidence among samples of exclusively Black MSM and TGW. The Brothers Study (HPTN 061), a multi-site study of Black MSM and a limited number of Black TGW

across the US with a site in Atlanta, GA, found that age and condomless receptive anal intercourse with HIV-positive or unknown status partners were independently associated with HIV seroconversion [19]. Among the uConnect cohort of 393 young (aged 16–29 years), Black MSM in Chicago, having at least one older (≥ 10 years older) sexual partner was the only predictor independently associated with HIV seroconversion [20]. Further research to understand predictors of HIV acquisition among Black MSM and TGW are urgently needed to inform HIV prevention interventions, including research on the potential role of substance use.

Other research among racially and ethnically diverse cohorts of MSM have shown specific types of substance use (e.g., stimulants, amyl nitrites) to be positively associated with HIV seroconversion [21–23]. Substance use could increase HIV infection through various behavioral and biological pathways. For example, past research suggests that substance use is associated with an increase in sexual risk behaviors (e.g., decreased condom use, increased number of sexual partners, increased likelihood of exchanging sex for money, goods, and/or services) [26–28]. Substance use has also been shown to amplify biological vulnerability through STI acquisition, as well as rectal inflammation and immune dysregulation [29, 30]. Taken together, these studies suggest that, while substance use does not account for racial disparities in HIV burden among sexual minorities [31], substance use might increase risk of HIV incidence within disparately impacted populations. Further research focused on the role of substance use in HIV infection among Black MSM and TGW is urgently needed, especially types of substance use that have been found to be highly prevalent among Black sexual minority groups, such as heavy drinking and marijuana use [32, 33].

Therefore, the objective of the current study was to examine substance use as a risk factor for HIV seroconversion in a cohort of Black MSM and TGW. We assessed whether different types of substance use were predictors of HIV seroconversion. Subsequently, we explored whether any associations between substance use and HIV seroconversion were independent of other sociodemographic characteristics, or attenuated by other HIV risk behaviors, including STI status. Finally, we stratified HIV seroconversion as a function of different age groups, given the observed disparities in HIV incidence [8, 9, 19], and explored these same relationships within different age categories.

Methods

Population

The data were drawn from a two-arm randomized controlled trial design to assess the effect of a sexual risk reduction

intervention for STI prevention among Black MSM and TGW in Atlanta, GA, USA metropolitan and surrounding areas between December 2012 and November 2014, which has been fully described previously [34]. The intervention was found to have no effect on biologically confirmed STI outcomes at long term follow ups (i.e., over 1 year) or HIV [34].

Potential study participants were enrolled via Lesbian, Gay, Bisexual, Transgender, Queer (LGBTQ) venues (such as bars), via dating applications (such as Grindr), and by posted fliers and word-of-mouth. Eligible participants were 18 years of age or older, assigned male gender at birth, identified as male or transgender female, reported HIV-negative or unknown serostatus, and had two or more male sex partners in the past year with at least one condomless anal sex act in the previous year. All participants included in this study were confirmed HIV-negative using an OraQuick ADVANCE Rapid HIV 1/2 Antibody Test at study enrollment, and then tested for HIV at 12-month post-enrollment using the same test. For these analyses, we include all participants who reported identifying as Black or African American and who tested for HIV at post-enrollment.

Procedures

All study procedures were conducted at a community-based research site. Participants completed a computerized assessment and STI testing at baseline. Interview questions solicited information on sociodemographic characteristics, substance use and HIV risk behaviors. Nucleic acid amplification testing (NAAT) was conducted to test participants for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using self-collected samples of urine and rectal swabs [35]. HIV testing was performed at baseline and 12-month post-enrollment using the OraQuick ADVANCE Rapid HIV 1/2 Antibody Test. Participants were compensated \$45 for each assessment. Baseline data from all participants was used to predict HIV seroconversion by 12-months. All study protocols received Institutional Review Board approval and the trial was registered in the clinical trials registry, clinicaltrials.gov (NCT02128594). All participants provided written informed consent.

Measures

HIV seroconversion was defined as a positive test at the 12-month study assessment point using an OraQuick ADVANCE Rapid HIV 1/2 Antibody Test.

Substance use was determined by asking participants how often in the past 3 months they had used: marijuana, stimulants (crack, cocaine, or methamphetamine), poppers (nitrile inhalants), erectile dysfunction medications regardless of a prescription, any injection drugs, or other drugs.

Responses were dichotomized to used at least once in the past 3 months and never used in the past 3 months, except for marijuana use, which was the most prevalent form of substance use, and was thus dichotomized to daily use and less than daily use. Alcohol use was assessed using the 3-item Alcohol Use Disorders Identification Test – Consumption (AUDIT-C) [36, 37]. The AUDIT-C consists of three items on drinking quantity and frequency, including binge drinking; an AUDIT-C score of ≥ 4 was considered indicative of unhealthy alcohol use [38, 39].

HIV risk behaviors were determined by asking participants whether (yes/no) they had, in the past 3 months: engaged in substance use (drugs or alcohol) before or during sex and engaged in group sex. In addition, participants reported the number of male sex partners and number of condomless sex acts they had in the past 3 months. Finally, participants were asked if they ever tested for HIV outside of the study (yes/no), and if they were currently taking PrEP (yes/no). *Chlamydia trachomatis* and *Neisseria gonorrhoeae* results were categorized as a composite of any baseline rectal or urine STI (yes/no).

Participants also reported on age, gender identity, sexual orientation, relationship status, education, income, and symptoms of depression (using the 10-item Center for Epidemiological Studies Depression Scale Revised (CES-D) [40], ≥ 10 was used as cut-off, Cronbach's $\alpha = 0.82$).

Statistical Analyses

We summarized sociodemographic characteristics, substance use, and HIV risk behaviors and compared the distribution of these factors by HIV seroconversion using χ^2 , Fisher's exact, and Wilcoxon tests. For multivariable analyses, all sociodemographic characteristics were controlled for, except for age category, which was conceptualized as an effect modifier because of previously reported variation in HIV seroconversion rates by age among Black MSM [8, 9, 19]. Initially, all types of substance use were entered into a binary logistic regression model with HIV seroconversion as the outcome to estimate odds ratios (OR), and 95% confidence intervals (CI). Any type of substance use associated with HIV seroconversion at $P < 0.20$ was then included in a multivariable model to estimate adjusted odds ratios (aOR) and 95% CI. Subsequently, HIV risk behaviors were entered into these multivariable models, one at a time, and the extent to which they attenuated the relationship between substance use and HIV seroconversion was evaluated by the change in the aOR due to the addition of the covariate. Factors that attenuated the aOR by $\geq 5\%$, were considered meaningful explanatory variables [41]. Supplementary analyses stratified by age category were run to assess predictors of HIV seroconversion within age categories. Statistical tests were

2-sided and $P < 0.05$ was considered statistically significant. SAS 9.4 was used for all statistical analyses.

Results

Sample Characteristics

Table 1 shows baseline sample characteristics, overall and by HIV conversion. Most participants were MSM (93.7%), and a proportion (7.3%) were TGW. There was a fairly even distribution among age categories. Fewer than half (47.7%) were employed. One in four (25.9%) had an annual income of less than \$20,000. One in four (24.9%) were homeless. Nearly half (49.0%) screened positive for symptoms of depression.

HIV Seroconversion

By 12-months follow-up, 5.3% of participants ($n = 24$) had seroconverted. By age group, 10.4% ($n = 13$) of 18–24-year-olds seroconverted, 7.3% ($n = 8$) of 25–29-year-olds, 1.6% ($n = 1$) of 30–39-year-olds seroconverted, and 1.0% ($n = 2$) of participants who were 40 years of age and older.

Substance Use and HIV Seroconversion

Table 2 shows baseline prevalence of substance use, overall and by HIV seroconversion. One in ten (10.5%) participants had an AUDIT-C score of 4 or more, an indicator of unhealthy drinking. Among all participants, 52.3% reported any marijuana use (data not shown in Table), with 11.8% reporting daily marijuana use, 26.5% reporting stimulant

Table 1 Sociodemographic characteristics and HIV seroconversion among $n = 449$ Black men who have sex with men (MSM) and transgender women (TGW) in Atlanta, GA, 2012–2014

	All participants ($n = 449$)		HIV – ($n = 425$)		HIV+ ($n = 24$)		χ^2	
	%	<i>N</i>	Row %	<i>N</i>	Row %	<i>N</i>	Value	<i>p</i>
Gender							0.036	0.85
Men who have sex with men (MSM)	92.7%	416	94.7%	394	5.3%	22		
Transgender women (TGW)	7.3%	33	93.9%	31	6.1%	2		
Age range (years)							13.806	0.007 ^a
18–24	27.8%	125	89.6%	112	10.4%	13		
25–29	24.3%	109	92.7%	101	7.3%	8		
30–39	14.0%	63	98.4%	62	1.6%	1		
40+	33.9%	152	98.7%	150	1.3%	2		
Sexual orientation							0.787	0.55
Homosexual/gay or bisexual	85.5%	382	94.2%	360	5.8%	22		
Heterosexual	14.5%	65	96.9%	63	3.1%	2		
Education							0.264	0.61
Less than college	36.7%	165	93.9%	155	6.1%	10		
Some college or more	63.3%	284	95.1%	270	4.9%	14		
Current employment status							1.158	0.33
Disability/unemployed/other	52.3%	235	95.7%	225	4.3%	10		
Employed/student	47.7%	214	93.5%	200	6.5%	14		
Annual income							0.011	0.92
> \$20,000	74.1%	329	94.5%	311	5.5%	18		
≤ \$20,000	25.9%	115	94.8%	109	5.2%	6		
Current housing stability							0.229	0.63
Stable/permanent	75.1%	337	94.4%	318	5.6%	19		
Homeless	24.9%	112	95.5%	107	4.5%	5		
Current relationship status							2.970	0.085
In a relationship	27.8%	125	97.6%	122	2.4%	3		
Not in a relationship	72.2%	324	93.5%	303	6.5%	21		
Depression (CES-D Score ≥ 10)							1.340	0.25
No	51.0%	228	93.4%	213	6.6%	15		
Yes	49.0%	219	95.9%	210	4.1%	9		

^aDenotes statistical significance at an $\alpha = 0.05$

Table 2 Bivariate and multivariable associations between substance use and HIV seroconversion among n=449 Black men who have sex with men (MSM) and transgender women (TGW) in Atlanta, GA, 2012–2014

	All Parti- pants (n = 449)		HIV– (n = 425)		HIV+ (n = 24)		χ^2		Multivariable ^a		
	%	N	Row %	N	Row %	N	Value	p	aOR	95% CI	P
Positive AUDIT score (≥ 4)							0.145	0.70			0.56
No	10.5%	47	91.5%	43	8.5%	4			Reference		
Yes	89.5%	401	95.0%	381	5.0%	20			1.29	0.54–3.09	
Daily marijuana use							4.241	0.039 ^b			0.030 ^b
No	88.2%	396	95.5%	378	4.5%	18			Reference		
Yes	11.8%	53	88.7%	47	11.3%	6			3.07	1.11–8.48	
Stimulants (cocaine, crack, meth- amphetamine)							1.065	0.30			0.53
No	74.4%	334	94.0%	314	6.0%	20			Reference		
Yes	25.6%	115	96.5%	111	3.5%	4			0.68	0.21–2.23	
Poppers							2.412	0.25			
No	91.3%	410	94.1%	386	5.9%	24					
Yes	8.7%	39	100.0%	39	0.0%	0					
Erectile dysfunction medications							3.035	0.061			
No	89.3%	401	94.0%	377	6.0%	24					
Yes	10.7%	48	100.0%	48	0.0%	0					
Other drugs							0.138	0.71			0.84
No	81.2%	381	94.5%	341	5.5%	20			Reference		
Yes	18.8%	88	95.5%	84	4.5%	4			1.13	0.35–3.64	
Any injection drug use							0.460	0.50			
No	98.2%	441	94.6%	417	5.4%	24					
Yes	1.8%	8	100.0%	8	0.0%	0					

^aTypes of substance use with no seroconversions were not included in the multivariable model because they interfered with model convergence

^bDenotes statistical significance at an $\alpha=0.05$

use, and 8.7% reporting use of poppers. Furthermore, 10.7% of participants reported use of erectile dysfunction medications (EDM), 1.8% reported any injection drug use, and 18.8% reported other drug use.

In bivariate analysis, 11.3% of participants who reported daily marijuana use seroconverted compared to 4.5% of participants who did not report daily marijuana use, a difference that was statistically significant ($P=0.039$). In multivariable analysis including all types of substance use, daily marijuana use remained positively associated with HIV seroconversion (aOR 2.85, 95% CI 1.07–7.61, $P=0.036$). No other type of substance use was associated with HIV seroconversion.

HIV Risk Behaviors and HIV Seroconversion

Table 3 shows baseline prevalence of HIV risk behaviors, overall and by HIV seroconversion. Most participants had tested for HIV (84.2%) and had engaged in substance use before having sex (78.0%). A considerable portion of the sample had sex in exchange for goods (29.9%), had engaged in group sex (26.3%), and had a laboratory-confirmed STI

(12.7%). Five participants (1.1%) were currently taking PrEP.

In bivariate analysis, 14.0% of participants with a laboratory-confirmed STI seroconverted compared to 4.5% of participants who did not, a difference that was statistically significant ($P=0.002$). No other HIV risk behaviors were associated with HIV seroconversion. In multivariable analysis, having a laboratory-confirmed STI was positively associated with HIV seroconversion (aOR 3.11, 95% CI 1.22–7.96, $P=0.018$).

Daily Marijuana Use and HIV Seroconversion: Behavioral and Biological Explanatory Factors

Daily marijuana use was positively associated with HIV seroconversion (aOR 3.07, 95% CI 1.11–8.48, $P=0.030$). As the only type of substance use positively associated with HIV seroconversion, we explored whether the association between daily marijuana use and HIV seroconversion was attenuated by other HIV risk behaviors (see Fig. 1). The association between daily marijuana use and HIV

Table 3 Bivariate and multivariable associations between HIV-related behaviors and HIV seroconversion among n=449 Black men who have sex with men (MSM) and transgender women (TGW) in Atlanta, GA, 2012–2014

	All Participants (n = 449)		HIV– (n = 425)		HIV+ (n = 24)		χ^2		Multivariable ^a		
	%	N	Row %	N	Row %	N	Value	p	aOR	95% CI	P
Tested for HIV (ever)							0.014	0.78			0.79
No	15.8%	71	94.4%	67	5.6%	4			Reference		
Yes	84.2%	378	94.7%	358	5.3%	20			1.17	0.37–3.69	
	SD	Mean	SD	Mean	SD	Mean					
Number of male sex partners	3.9	4.5	3.8	4.6	4.1	3.0	0.36	0.71	1.01	0.93–1.10	0.81
Number of condomless sex acts	5.8	12.7	5.9	13.0	3.9	3.8	2.03	0.047	0.98	0.92–1.05	0.55
	%	N	Row %	N	Row %	N					
Substance use before sex							0.022	0.88			0.58
No	22.0%	99	94.9%	94	5.1%	5			Reference		
Yes	78.0%	350	94.6%	331	5.4%	19			0.78	0.31–1.92	
Had sex in exchange for goods							0.289	0.59			0.91
No	70.1%	312	94.2%	294	5.8%	18			Reference		
Yes	29.9%	133	95.5%	127	4.5%	6			0.94	0.33–2.69	
Engaged in group sex							1.223	0.27			0.42
No	73.7%	330	93.9%	310	6.1%	20			Reference		
Yes	26.3%	118	96.6%	114	3.4%	4			0.63	0.21–1.93	
Current PrEP use							0.285	1.000			0.82
No	98.9%	444	94.6%	420	5.4%	24			Reference		
Yes	1.1%	5	100.0%	5	0.0%	0			1.45	0.06–34.16	
Any sexually transmitted infections							9.744	0.002 ^b			0.018 ^b
No	87.3%	392	95.9%	376	4.1%	16			Reference		
Yes	12.7%	57	86.0%	49	14.0%	8			3.11	1.22–7.96	

^aMultivariable analyses controlled for all sociodemographic characteristics, except for age category, which was conceptualized as an effect modifier

^bDenotes statistical significance at an $\alpha=0.05$

seroconversion was attenuated when accounting for having a laboratory-confirmed STI (reduction in aOR 5.3%), although the association remained statistically significant ($P=0.042$). The association between daily marijuana use and HIV seroconversion was not attenuated when accounting for any other HIV risk behavior.

Supplementary Analyses

We assessed the prevalence of daily marijuana use and its association with HIV seroconversion among the different age categories (Table 4). To summarize, daily marijuana use was considerable in each age category (18.4%, 13.8% and 15.9%, respectively) except for 40 years of age and older (3.3%). Daily marijuana use was positively associated with HIV seroconversion in all age groups except among participants who were 40 years of age and older, although no associations achieved statistical significance. No baseline sociodemographic characteristics or other HIV risk

behaviors were associated with HIV seroconversion within any age category.

Discussion

Among our community-based cohort of Black MSM and TGW with recent HIV risk behavior in the Atlanta metropolitan and surrounding areas, HIV incidence was high: 5.3% of participants (24 out of 449 individuals) seroconverted over the course of the one-year study. Daily marijuana use was associated with a more than threefold increased odds of HIV seroconversion. This association was not explained by other HIV risk behaviors, although it was attenuated when controlling for laboratory-confirmed STI. No other types of drug use predicted HIV seroconversion.

This level of HIV incidence is higher than what was reported among Black MSM in HPTN 061, where a 3.0% HIV incidence rate (95% CI 2.0–4.4%) was observed [19].




Fig. 1 Adjusted odds ratios for daily marijuana use and HIV seroconversion from multivariable models in a community-based sample of n=449 black MSM and TGW, Atlanta, 2012–2014. a. Yellow region indicates covariate-adjusted OR for daily marijuana use and HIV seroconversion that are between 0 and 5% less than the aOR for everyday marijuana use with just sociodemographic adjustment, whereas green region indicates covariate-adjusted OR that are more than 5%

less, indicating meaningful attenuation of the association between daily marijuana use and HIV seroconversion. b. The one factor that meaningfully attenuated the association between daily marijuana use and HIV seroconversion (laboratory-confirmed STI), is indicated in bold with an asterisk after its label. C. Even after adjustment by each covariate, daily marijuana use remains significantly associated with HIV seroconversion

Table 4 Bivariate associations between everyday marijuana use among age categories of n = 449 Black men who have sex with men (MSM) and transgender women (TGW) in Atlanta, GA, 2012–2014

	%	N	Row %	N	Row %	N	Fisher's	p	
Participants 18–24 years old	Total	(n = 125)	HIV– (n = 112)		HIV+ (n = 13)		0.088	1.000	
	No	81.6%	102	89.2%	91	10.8%			11
	Daily marijuana use	18.4%	23	91.3%	21	8.7%			2
Participants 25–29 years old	Total	(n = 109)	HIV– (n = 101)		HIV+ (n = 8)		4.100	0.078	
	No	86.2%	94	94.7%	89	5.3%			5
	Daily marijuana use	13.8%	15	80.0%	12	20.0%			3
Participants 30–39 years old	Total	(n = 63)	HIV– (n = 62)		HIV+ (n = 1)		5.385	0.16	
	No	84.1%	53	100.0%	53	0.0%			0
	Daily marijuana use	15.9%	10	90.0%	9	10.0%			1
Participants 40+ years old	Total	(n = 152)	HIV– (n = 150)		HIV+ (n = 2)		0.069	1.000	
	No	96.7%	147	98.6%	145	1.4%			2
	Daily marijuana use	3.3%	5	100.0%	5	0.0%			0

Supplementary analyses table

Both studies used recent HIV risk behavior as part of the inclusion criteria, although the criteria were slightly different (our study required that men report having two or more male sex partners in the past year with at least one condomless anal sex act in the previous year, whereas HPTN 061 included men who reported having at least one condomless anal sex act with a man in the previous 6 months). The observed level of HIV incidence in this study is lower than what was reported among Black MSM in the uConnect study, where HIV incidence was 8.5 cases per 100 PY (95% CI 6.0–11.9). Notably, though, the uConnect study was among Black MSM aged 16–29 years. Variation in results between the current study and others might also be due to distinct local context. Previous research has documented notable geographical differences in patterns of substance use [42], substance use disorder among individuals enrolled in HIV services [43, 44], and new HIV diagnoses among MSM [16, 45]. Geographic variation in trends in HIV prevalence among people who inject drugs have been shown to reflect policy differences, such as harm reduction approaches (e.g., needle exchange services) being more widely adopted in large Eastern and Midwestern metropolitan areas [46]. Relevant to the current study, Georgia has not yet acted to expand Medicaid coverage [47], which has been shown to be associated with improved outcomes for other health conditions [48], including a decline in new HIV diagnoses [49], and uptake of PrEP among high-risk populations for HIV infection [50]. Further research should explore the generalizability of these findings to other settings.

We also observed increased HIV incidence among younger Black MSM and TGW, which was also observed in HPTN 061 [19], and which aligns with HIV surveillance data that shows elevated HIV incidence among young Black MSM [8, 9]. Also, having a laboratory-confirmed STI was associated with a more than threefold increased odds of HIV seroconversion, a long-standing a well-documented risk factor for HIV infection among MSM [51, 52].

The observed association between frequent marijuana use and HIV seroconversion is novel in that, prior research with predominantly white MSM has found that stimulants, amyl nitrites, and erectile dysfunction medications are associated with faster HIV incidence but not marijuana use [21–23]. There are multiple potential pathways through which marijuana use could contribute to HIV incidence. Marijuana use could potentially contribute to increases in HIV risk behaviors, as has been shown with other types of substance use [53], including among Black MSM [54, 55]. Any marijuana use has previously been associated with participation in HIV risk behaviors among Black MSM [56], and heavy marijuana use has been associated with being HIV positive and unaware of one's status among Black MSM [57]. In contrast, our results suggest that HIV risk behaviors did not attenuate the increased level of HIV incidence among

daily marijuana users. Alternatively, heavy marijuana use among Black MSM has been found to increase the number of connections to other Black MSM in a HIV transmission cluster, suggesting that heavy marijuana use could expose Black MSM to social networks with increased risk of HIV exposure [58]. We were not able to explore this particular hypothesis with these data. Future research should consider focusing on Black MSM and TGW who are at risk for HIV and who use marijuana frequently. This research could also measure marijuana use with more granularity, including modes (e.g., vaping, smoking blunts, edibles) and quantity of use.

Marijuana use could also contribute to HIV incidence by increasing biological vulnerability to HIV infection. Other substance use has been shown to amplify biological vulnerability for HIV/STI acquisition, through rectal inflammation and immune dysregulation [29, 30]. However, marijuana use has been shown to have a beneficial biological impact on systemic inflammation [59–62]. Polysubstance use may also be particularly important with regards to this biological vulnerability, although it is much less studied [63–66], including in our analyses. Our finding that laboratory-confirmed STI was found to reduce the association between daily marijuana use and HIV incidence suggests that this is a plausible mechanism. Integrated bio-behavioral research into how marijuana use might contribute to biological vulnerability to HIV infection is urgently needed, including in the context of PrEP use, other STIs, and sexual behavior.

One additional pathway through which marijuana use could contribute to HIV incidence is by negatively impacting PrEP uptake and adherence. PrEP was not associated with HIV seroconversion in our study, and it did not attenuate the association between daily marijuana use and HIV seroconversion, although very few participants were currently using PrEP. This is likely because data was collected in 2012–2014, while PrEP was approved by the FDA in 2012 [67]. PrEP awareness and utilization has been increasing in recent years [69–71], although concerns remain about PrEP uptake and adherence being sub-optimal among populations at risk [72–74], especially Black MSM and TGW [75–77]. Relationships between marijuana use and PrEP should continue to be explored further, particularly using more recent data, as PrEP uptake increases.

The strong association observed between frequent marijuana use and HIV seroconversion raises a critical issue because marijuana use, including frequent marijuana use, has been found to be prevalent in Black MSM [33, 78]. Furthermore, marijuana is already a large industry in the US, currently estimated at \$8 billion per year [79], and it is greatly expanding, such that it is expected to triple by 2025 [80], because of increasing legalization. Thus far, 13 states have fully legalized cannabis for recreational use. Legalization of marijuana appears to increase the prevalence of

marijuana use among adults [81–84], as well as other types of substance use [85]. Marijuana legalization is also changing modes of use and the potency of products used [86]. These changing laws also seem to differentially impact sexual and gender minorities [33, 78]. While individuals can use marijuana without harm [87], and some report beneficial effects from use [88–91], many also experience negative health consequences [92, 93]. The potential contribution of marijuana to HIV transmission, and to racial disparities in HIV burden, is an area that merits further research.

There are limitations to this study. First, the use of self-reported substance use as the primary exposure would be stronger if it were confirmed using objective biomarker data. Participants likely under-reported their substance use, which research has shown that there are issues with the validity of self-reported substance use, including marijuana use, among Black MSM living in Atlanta, GA [94]. Under-reporting of substance use, however, likely would have biased any observed associations towards the null [95]. Furthermore, future researchers might consider using more robust measures of substance use beyond frequency of use, including measures that index problematic patterns of substance use. For example, the Cannabis Use Disorders Identification Test (CUDIT) can be used to screen for hazardous cannabis use [96]. Future researchers could also measure the context of substance use. For example, previous research has shown that the reasons that Black MSM engage in substance use, including marijuana use, are relevant to their sexual behavior [56, 97]. Assessing substance use more robustly in these ways would also allow future researchers to explore whether there are sub-groups with different risk profiles. Second, this sample was not intended to be representative of Black MSM and TGW in Atlanta, GA or other areas, thus also potentially limiting generalizability of the findings. Third, we used the same recruitment strategy for both MSM and TGW, and only 7.3% of study participants identified as TGW. We acknowledge that Black MSM and TGW are distinct populations [98, 99], with unique HIV prevention needs [100, 101]. Because relatively little research in this area has included TGW, particularly TGW of color, we felt that it was important to include them in the analyses. However, the study was under-powered to be able to assess possible differences between Black MSM and TGW, an area for future research that would require larger samples of TGW. Lastly, this paper is reporting data collected in 2012–2014 and future research should explore the generalizability of these findings using more recent data given the many changes in domestic policies that have since taken place, such as the previously mentioned changes in the legalization of marijuana and Medicaid expansion, as well as other changes related to substance-related healthcare services (e.g., in response to the opioid

epidemic [102]) and ongoing advancements in HIV, prevention, detection and care.

Conclusions

Among a community-based sample of Black MSM and TGW living in the US Southeast, we observed a concerning high level of HIV seroconversion, and that daily marijuana use was associated with more than triple the odds of HIV seroconversion. Further research is needed to determine the underlying mechanisms linking marijuana use and HIV seroconversion among these disparately impacted populations, including research with a more nuanced look at marijuana use (e.g., amounts of marijuana used, modes of marijuana use, potency of marijuana consumed). Findings also underscore the potential benefits of expanded efforts to encourage more frequent HIV testing as well as PrEP use among Black MSM and TGW who use marijuana frequently.

Author Contributions JK wrote the manuscript. GH served as the lead statistician. GH, AWC, DTD, RJW and LAE assisted with data interpretation and read drafts of the paper. LAE served as the principal investigator for the project.

Funding The study reported on here were supported by a Grant from the National Institutes of Health (NIH) R01MH094230. Dr. Knox's effort on this project was supported by NIH Grants K01AA028199, R01DA054553, and R21DA053156. Dr. Duncan was supported in part by grants from the National Institute on Minority Health and Health Disparities (5R01MD013554-04 and 3R01MD013554-04S1), the National Institute on Mental Health (7R01MH112406-05), the National Institute on Drug Abuse (1R01DA054553-01) and the National Heart, Lung and Blood Institute (1R01HL160325-01). Dr. Watson was supported by NIH Grant K01DA047918. Dr. Eaton was supported by NIH Grants R01MH094230 and R01DA053168.

Data Availability The data underlying the results presented in the study are available upon request from Lisa Eaton, lisa.eaton@uconn.edu.

Code Availability The code used to achieve the results presented in the study is available upon request from Lisa Eaton, lisa.eaton@uconn.edu.

Declarations

Conflict of interest The authors have no conflicts of interest to declare.

Consent to Participate All participants provided written informed consent.

Consent for Publication The authors affirm that all participant signed informed consent regarding publishing their data.

Ethical Approval All study protocols received Institutional Review Board approval and the trial was registered in the clinical trials registry, clinicaltrials.gov (NCT02128594).

References

- Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. *JAMA*. 2019. <https://doi.org/10.1001/jama.2019.1343>.
- HIV Surveillance Report, 2019. Centers for disease control and prevention; 2021. <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-updated-vol-32.pdf>.
- Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas; 2013. *hiv surveillance report*. 2015; p. 25.
- Centers for Disease Control and Prevention. Estimated HIV incidence among adults and adolescents in the United States, 2007–2010. *HIV surveillance supplemental report*. 2012;17(4). <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-17-4.pdf>.
- Centers for Disease Control and Prevention. HIV among African American gay and bisexual men [Web]; 2015. <https://www.cdc.gov/hiv/group/msm/bmsm.html>. Accessed 27 Jan 2022.
- Centers for Disease Control and Prevention. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men—five U.S. cities, June 2004–April 2005. *MMWR Morb Mortal Wkly Rep*. 2005;54(24):597–601.
- Harawa N, Greenland S, Bingham T, Johnson D, Cochran S, Cunningham W, et al. Associations of race/ethnicity with HIV prevalence and HIV-related behaviors among young men who have sex with men in 7 urban centers in the United States. *J Acquir Immune Defic Syndr*. 2004;35(5):526–36.
- Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. *PLoS ONE*. 2011;6(8):e17502.
- Mitsch A, Singh S, Li J, Balaji A, Linley L, Selik R. Age-associated trends in diagnosis and prevalence of infection with HIV among men who have sex with men—United States, 2008–2016. *MMWR Morb Mortal Wkly Rep*. 2018;67(37):1025–31.
- Matthews DD, Herrick AL, Coulter RW, Friedman MR, Mills TC, Eaton LA, Wilson PA, Stall RD, Team PS. Running backwards Consequences of current HIV incidence rates for the next generation of black MSM in the United States. *AIDS Behav*. 2016;20(1):7–16. <https://doi.org/10.1007/s10461-015-1158-z>.
- Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *Lancet Infect Dis*. 2013;13(3):214–22.
- Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. *Am J Public Health*. 2019. <https://doi.org/10.2105/AJPH.2018.304727>.
- Poteat T, Reisner SL, Radix A. HIV epidemics among transgender women. *Curr Opin HIV AIDS*. 2014;9(2):168–73.
- Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global epidemiology of HIV infection and related syndemics affecting transgender people. *J Acquir Immune Defic Syndr*. 2016;72:S210–9.
- Schulden JD, Song B, Barros A, Mares-DelGrasso A, Martin CW, Ramirez R, et al. Rapid HIV testing in transgender communities by community-based organizations in three cities. *Public Health Rep*. 2008;123(Suppl 3):101–14.
- Rosenberg ES, Grey JA, Sanchez TH, Sullivan PS. Rates of prevalent HIV infection, prevalent diagnoses, and new diagnoses among men who have sex with men in US states, metropolitan statistical areas, and counties, 2012–2013. *JMIR Public Health Surveill*. 2016;2(1):e22.
- Goodreau SM, Rosenberg ES, Jenness SM, Luisi N, Stansfield SE, Millett GA, et al. Sources of racial disparities in HIV prevalence in men who have sex with men in Atlanta, GA, USA: a modelling study. *Lancet HIV*. 2017;4(7):e311–20.
- Sullivan PS, Rosenberg ES, Sanchez TH, Kelley CF, Luisi N, Cooper HL, et al. Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study. *Ann Epidemiol*. 2015;25(6):445–54.
- Koblin BA, Mayer KH, Eshleman SH, Wang L, Mannheimer S, del Rio C, et al. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. *PLoS ONE*. 2013;8(7):e70413.
- Lancki N, Almirol E, Alon L, McNulty M, Schneider JA. Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago. *AIDS*. 2018;32(3):383–92.
- Grov C, Westmoreland D, Morrison C, Carrico AW, Nash D. The crisis we are not talking about: one-in-three annual HIV seroconversions among sexual and gender minorities were persistent methamphetamine users. *J Acquir Immune Defic Syndr*. 2020;85(3):272–9.
- Buchbinder SP, Vittinghoff E, Heagerty PJ, Celum CL, Seage GR 3rd, Judson FN, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. *J Acquir Immune Defic Syndr*. 2005;39(1):82–9.
- Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K, et al. Risk factors for HIV infection among men who have sex with men. *AIDS*. 2006;20(5):731–9.
- Sewell J, Miltz A, Lampe FC, Cambiano V, Speakman A, Phillips AN, et al. Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. *Int J Drug Policy*. 2017;43:33–43.
- Boyer CB, Greenberg L, Chutuaape K, Walker B, Monte D, Kirk J, et al. Exchange of sex for drugs or money in adolescents and young adults: an examination of sociodemographic factors, HIV-related risk, and community context. *J Community Health*. 2017;42(1):90–100.
- Poteat T, Wirtz AL, Radix A, Borquez A, Silva-Santisteban A, Deutsch MB, et al. HIV risk and preventive interventions in transgender women sex workers. *Lancet*. 2015;385(9964):274–86.
- Yu G, Wall MM, Chiasson MA, Hirshfield S. Complex drug use patterns and associated HIV transmission risk behaviors in an Internet sample of U.S. men who have sex with men. *Arch Sex Behav*. 2015;44(2):421–8.
- Schneider J, Cornwell B, Jonas A, Lancki N, Behler R, Skaathun B, et al. Network dynamics of HIV risk and prevention in a population-based cohort of young Black men who have sex with men. *Netw Sci*. 2017;5(3):381–409.
- Fulcher JA, Shoptaw S, Makgoeng SB, Elliott J, Ibarroondo FJ, Ragsdale A, et al. Brief report: recent methamphetamine use is associated with increased rectal mucosal inflammatory cytokines, regardless of HIV-1 serostatus. *J Acquir Immune Defic Syndr*. 2018;78(1):119–23.
- Tapia GR, Glynn TR, Miller C, Manuzak JA, Broedlow CA, McLaugh A, et al. Syndemics and preexposure prophylaxis are independently associated with rectal immune dysregulation in sexual minority men. *AIDS*. 2021;35(8):1295–300.
- Millett GA, Flores SA, Peterson JL, Bakeman R. Explaining disparities in HIV infection among black and white men who have

- sex with men: a meta-analysis of HIV risk behaviors. *AIDS*. 2007;21(15):2083–91.
32. Schuler MS, Prince DM, Breslau J, Collins RL. Substance use disparities at the intersection of sexual identity and race/ethnicity: results from the 2015–2018 national survey on drug use and health. *LGBT Health*. 2020;7(6):283–91.
 33. Philbin MM, Mauro PM, Greene ER, Martins SS. State-level marijuana policies and marijuana use and marijuana use disorder among a nationally representative sample of adults in the United States, 2015–2017: sexual identity and gender matter. *Drug Alcohol Depend*. 2019;204:107506.
 34. Eaton LA, Kalichman SC, Kalichman MO, Driffin DD, Baldwin R, Zohren L, et al. Randomised controlled trial of a sexual risk reduction intervention for STI prevention among men who have sex with men in the USA. *Sex Transm Infect*. 2018;94(1):40–5.
 35. van der Helm JJ, Hoebe CJ, van Rooijen MS, Brouwers EE, Fennema HS, Thiesbrummel HF, et al. High performance and acceptability of self-collected rectal swabs for diagnosis of chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. *Sex Transm Dis*. 2009;36(8):493–7.
 36. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. *Arch Intern Med*. 1998;158(16):1789–95.
 37. Bradley KA, Kivlahan DR, Zhou XH, Sporleder JL, Epler AJ, McCormick KA, et al. Using alcohol screening results and treatment history to assess the severity of at-risk drinking in veterans affairs primary care patients. *Alcohol Clin Exp Res*. 2004;28(3):448–55.
 38. Dawson DA, Grant BF, Stinson FS, Zhou Y. Effectiveness of the derived alcohol use disorders identification test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. *Alcohol Clin Exp Res*. 2005;29(5):844–54.
 39. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res*. 2007;31(7):1208–17.
 40. Bjorgvinsson T, Kertz SJ, Bigda-Peyton JS, McCoy KL, Aderka IM. Psychometric properties of the CES-D-10 in a psychiatric sample. *Assessment*. 2013;20(4):429–36.
 41. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable methods. Belmont: Duxbury Press; 1988.
 42. Farrell M, Martin NK, Stockings E, Borquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. *Lancet*. 2019;394(10209):1652–67.
 43. Garner BR, Gotham HJ, Knudsen HK, Zulkiewicz BA, Tueller SJ, Berzofsky M, et al. The prevalence and negative impacts of substance use disorders among people with HIV in the United States: a real-time Delphi survey of key stakeholders. *AIDS Behav*. 2021. <https://doi.org/10.1007/s10461-021-03473-9>.
 44. Hartzler B, Dombrowski JC, Crane HM, Eron JJ, Geng EH, Christopher Mathews W, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. *AIDS Behav*. 2017;21(4):1138–48.
 45. Jones J, Grey JA, Purcell DW, Bernstein KT, Sullivan PS, Rosenberg ES. Estimating prevalent diagnoses and rates of new diagnoses of HIV at the state level by age group among men who have sex with men in the United States. *Open Forum Infect Dis*. 2018;5(6):ofy124.
 46. Williams LD, Ibragimov U, Tempalski B, Stall R, Satcher Johnson A, Wang G, et al. Trends over time in HIV prevalence among people who inject drugs in 89 large US metropolitan statistical areas, 1992–2013. *Ann Epidemiol*. 2020;45:12–23.
 47. Status of State Medicaid Expansion Decisions: Interactive map [Internet]. Kaiser Family Foundation. 2021. <https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/>. Accessed 30 Dec 2021.
 48. Baldwin LM, Larson EH, Connell FA, Nordlund D, Cain KC, Cawthon ML, et al. The effect of expanding medic-aid prenatal services on birth outcomes. *Am J Public Health*. 1998;88(11):1623–9.
 49. Cahill SR, Mayer KH, Boswell SL. The Ryan white HIV/AIDS program in the age of health care reform. *Am J Public Health*. 2015;105(6):1078–85.
 50. Siegler AJ, Mehta CC, Mouhanna F, Giler RM, Castel A, Pemberton E, et al. Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018. *Ann Epidemiol*. 2020;45:24–31.
 51. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sex Transm Dis*. 1992;19(2):61–77.
 52. Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, et al. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. *Clin Infect Dis*. 2014;59(7):1020–6.
 53. Compton WM, Jones CM. Substance use among men who have sex with men. *N Engl J Med*. 2021;385(4):352–6.
 54. Hermanstynne KA, Green HD Jr, Tieu HV, Hucks-Ortiz C, Wilton L, Shoptaw S. The association between condomless anal sex and social support among black men who have sex with men (MSM) in six U.S. cities: a study using data from the HIV prevention trials network BROTHERS study (HPTN 061). *AIDS Behav*. 2019;23(6):1387–95.
 55. Mimiaga MJ, Reisner SL, Fontaine YM, Bland SE, Driscoll MA, Isenberg D, et al. Walking the line: stimulant use during sex and HIV risk behavior among Black urban MSM. *Drug Alcohol Depend*. 2010;110(1–2):30–7.
 56. Morgan E, Skaathun B, Michaels S, Young L, Khanna A, Friedman SR, et al. Marijuana use as a sex-drug is associated with HIV risk among black MSM and their network. *AIDS Behav*. 2016;20(3):600–7.
 57. Morgan E, Khanna AS, Skaathun B, Michaels S, Young L, Duvoisin R, et al. Marijuana use among young black men who have sex with men and the HIV care continuum: findings from the uConnect cohort. *Subst Use Misuse*. 2016;51(13):1751–9.
 58. Morgan E, Nyaku AN, D'Aquila RT, Schneider JA. Determinants of HIV phylogenetic clustering in Chicago among young black men who have sex with men from the uConnect cohort. *J Acquir Immune Defic Syndr*. 2017;75(3):265–70.
 59. Chen W, Crawford RB, Kaplan BL, Kaminski NE. Modulation of HIVGP120 antigen-specific immune responses in vivo by Delta9-tetrahydrocannabinol. *J Neuroimmune Pharmacol*. 2015;10(2):344–55.
 60. Manuzak JA, Gott TM, Kirkwood JS, Coronado E, Hensley-McBain T, Miller C, et al. Heavy cannabis use associated with reduction in activated and inflammatory immune cell frequencies in antiretroviral therapy-treated human immunodeficiency virus-infected individuals. *Clin Infect Dis*. 2018;66(12):1872–82.
 61. Milloy MJ, Marshall B, Kerr T, Richardson L, Hogg R, Guillemi S, et al. High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs. *Drug Alcohol Rev*. 2015;34(2):135–40.
 62. Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. *J Neuroimmune Pharmacol*. 2013;8(3):608–20.
 63. Green KM, Musci RJ, Matson PA, Johnson RM, Reboussin BA, Ialongo NS. Developmental patterns of adolescent marijuana and alcohol use and their joint association with sexual

- risk behavior and outcomes in young adulthood. *J Urban Health*. 2017;94(1):115–24.
64. Andrade LF, Carroll KM, Petry NM. Marijuana use is associated with risky sexual behaviors in treatment-seeking polysubstance abusers. *Am J Drug Alcohol Abuse*. 2013;39(4):266–71.
 65. Dir AL, Gilmore AK, Moreland AD, Davidson TM, Borkman AL, Rheingold AA, et al. What's the harm? Alcohol and marijuana use and perceived risks of unprotected sex among adolescents and young adults. *Addict Behav*. 2018;76:281–4.
 66. Swartzendruber A, Sales JM, Brown JL, DiClemente RJ, Rose ES. Comparison of substance use typologies as predictors of sexual risk outcomes in African American adolescent females. *Arch Sex Behav*. 2016;45(1):63–72.
 67. Grov C, Westmoreland DA, D'Angelo AB, Pantalone DW. How has HIV pre-exposure prophylaxis (PrEP) changed sex? A review of research in a new era of bio-behavioral HIV prevention. *J Sex Res*. 2021. <https://doi.org/10.1080/00224499.2021.1936440>.
 68. Delaney KP, Sanchez T, Bowles K, Oraka E, DiNenno E, Sullivan PS. Awareness and use of PrEP appear to be increasing among internet samples of US MSM. In: Conference on retroviruses and opportunistic infections; Boston, Massachusetts; 2016.
 69. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV pre-exposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis*. 2017;64(2):144–9.
 70. Sullivan PS, Giler RM, Mouhanna F, Pembleton ES, Guest JL, Jones J, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. *Ann Epidemiol*. 2018;28(12):833–40.
 71. Sullivan PS, Mouhanna F, Mera R, Pembleton E, Castel AD, Jaggi C, et al. Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. ending the HIV epidemic jurisdictions. *Ann Epidemiol*. 2020;44:16–30.
 72. Misra K, Udeagu C-C. Disparities in awareness of HIV post-exposure and pre-exposure prophylaxis among notified partners of HIV-positive individuals, New York City 2015–2017. *JAIDS J Acquir Immune Defic Syndr*. 2017;76(2):132–40.
 73. Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. *Ann Epidemiol*. 2018;28(12):841–9.
 74. Harris NS, Johnson AS, Huang Y-LA, Kern D, Fulton P, Smith DK, et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV pre-exposure prophylaxis—United States, 2013–2018. *Morb Morta Wkly Rep*. 2019;68(48):1117.
 75. Finlayson T, Cha S, Xia M, Trujillo L, Denson D, Prejean J, et al. Changes in HIV pre-exposure prophylaxis awareness and use among men who have sex with men—20 Urban areas, 2014 and 2017. *MMWR Morb Mortal Wkly Rep*. 2019;68(27):597–603.
 76. Kanny D, Jeffries WL, Chapin-Bardales J, Denning P, Cha S, Finlayson T, et al. Racial/ethnic disparities in HIV pre-exposure prophylaxis among men who have sex with men—23 urban areas, 2017. *MMWR Morb Mortal Wkly Rep*. 2019;68(37):801–6.
 77. Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. *AIDS Care*. 2018;30(1):9–17.
 78. Philbin MM, Mauro PM, Greene ER, LaBossier NJ, Giovenco DP, Martins SS. Medical cannabis laws and medical and non-medical prescription stimulant use among a nationally representative sample of US Adults: Examining the role of sexual identity and gender. *Int J Drug Policy*. 2020;84:102861.
 79. Moon A, Prentice C. High tech, high finance and high times for U.S. pot industry. London: Reuters; 2017.
 80. Kagia J. Financial analysis and prospects for the cannabis industry. In: Panel presentation; multifaceted effects of the developing cannabis market symposium; February 15; Yale University; New Haven, CT2018.
 81. Hasin DS, Sarvet AL, Cerda M, Keyes KM, Stohl M, Galea S, et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991–1992 to 2012–2013. *JAMA Psychiat*. 2017;74(6):579–88.
 82. Martins SS, Mauro CM, Santaella-Tenorio J, Kim JH, Cerda M, Keyes KM, et al. State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S. population. *Drug Alcohol Depend*. 2016;169:26–32.
 83. Cerda M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. Association between recreational marijuana legalization in the united states and changes in marijuana use and cannabis use disorder from 2008 to 2016. *JAMA Psychiat*. 2019. <https://doi.org/10.1001/jamapsychiatry.2019.3254>.
 84. Mauro CM, Newswanger P, Santaella-Tenorio J, Mauro PM, Carliner H, Martins SS. Impact of medical marijuana laws on state-level marijuana use by age and gender, 2004–2013. *Prev Sci*. 2019;20(2):205–14.
 85. Segura LE, Mauro CM, Levy NS, Khauli N, Philbin MM, Mauro PM, et al. Association of US medical marijuana laws with non-medical prescription opioid use and prescription opioid use disorder. *JAMA Netw Open*. 2019;2(7):e197216.
 86. Reboussin BA, Wagoner KG, Sutfin EL, Suerken C, Ross JC, Egan KL, et al. Trends in marijuana edible consumption and perceptions of harm in a cohort of young adults. *Drug Alcohol Depend*. 2019;205:107660.
 87. Fergusson DM, Boden JM, Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. *Soc Psychiatry Psychiatr Epidemiol*. 2015;50(9):1317–26.
 88. Azcarate PM, Zhang AJ, Keyhani S, Steigerwald S, Ishida JH, Cohen BE. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US population. *J Gen Intern Med*. 2020;35(7):1979–86.
 89. Keyhani S, Steigerwald S, Ishida J, Vali M, Cerdá M, Hasin D, et al. Risks and benefits of marijuana use: a national survey of U.S. adults. *Ann Intern Med*. 2018;169(5):282–90.
 90. Prentiss D, Power R, Balmes G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. *J Acquir Immune Defic Syndr*. 2004;35(1):38–45.
 91. Orsolini L, Chiappini S, Volpe U, Berardis D, Latini R, Papanti GD, et al. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. *Medicina (Kaunas)*. 2019;55(9):525.
 92. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. *JAMA Psychiat*. 2016;73(3):292–7.
 93. Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions-III. *Am J Psychiatry*. 2016;173(6):588–99.
 94. White D, Rosenberg ES, Cooper HL, del Rio C, Sanchez TH, Salazar LF, et al. Racial differences in the validity of self-reported drug use among men who have sex with men in Atlanta. *GA Drug Alcohol Depend*. 2014;138:146–53.

95. Rothman KJ. *Epidemiology: an introduction*. Oxford: Oxford University Press; 2012.
96. Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the cannabis use disorders identification test (CUDIT) in an alcohol-dependent clinical sample. *Drug Alcohol Rev*. 2003;22(3):309–15.
97. Knox J, Reddy V, Lane T, Hasin D, Sandfort T. Substance use and sexual risk behavior among black South African men who have sex with men: the moderating effects of reasons for drinking and safer sex intentions. *AIDS Behav*. 2017;21(7):2023–32.
98. Ezell JM, Ferreira MJ, Duncan DT, Schneider JA. The social and sexual networks of black transgender women and black men who have sex with men: results from a representative sample. *Transgend Health*. 2018;3(1):201–9.
99. Russell JS, Hickson DA, Timmins L, Duncan DT. Higher rates of low socioeconomic status, marginalization, and stress in black transgender women compared to black cisgender MSM in the MARI Study. *Int J Environ Res Public Health*. 2021;18(4):2183.
100. Khalili J, Leung LB, Diamant AL. Finding the perfect doctor: identifying lesbian, gay, bisexual, and transgender-competent physicians. *Am J Public Health*. 2015;105(6):1114–9.
101. Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. *J Int AIDS Soc*. 2016;19:21105. <https://doi.org/10.7448/IAS.19.7.21105>.
102. Schuler MS, Heins SE, Smart R, Griffin BA, Powell D, Stuart EA, et al. The state of the science in opioid policy research. *Drug Alcohol Depend*. 2020;214:108137.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.